Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

163
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
163
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

119
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
119
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
127
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

141
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
141

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Appendectomy and Subsequent Type 2 Diabetes - A National Cohort study.

The Journal of surgical research·2026
Same author

Safety Profile of Zavegepant in the Treatment of Acute Migraine: Insights from the FDA Adverse Event Monitoring System Database.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Benefit-risk balance of advanced therapies in pediatric inflammatory bowel disease: evidence and gaps versus adults.

Inflammatory bowel diseases·2026
Same author

Reply.

Gastroenterology·2026
Same author

Global phenotypic similarity in inflammatory bowel disease: the Eastern Mediterranean region perspective.

Journal of Crohn's & colitis·2026
Same author

Interleukin-10 Autoantibodies and HLA-DRB1*01:03 in Inflammatory Bowel Disease.

The New England journal of medicine·2026
Same journal

Barriers and Facilitators for Equitable Clinical Research Among Pragmatic Trialists: A Qualitative Study.

Pragmatic and observational research·2026
Same journal

The Potential Impact of GLP-1 Receptor Agonists on Exacerbation Risk in Patients with COPD and Type 2 Diabetes: A Real-World Population-Based Observational Study.

Pragmatic and observational research·2026
Same journal

Development and Internal Validation of a Prediction Model for Major Cardiovascular and Respiratory Events in Chronic Obstructive Pulmonary Disease: Nationwide Primary Care Electronic Medical Records Cohort Study.

Pragmatic and observational research·2026
Same journal

Validity of Using Prescription Medications to Classify Disease - A Retrospective Observational Study Using Routinely Collected Electronic Health Records from the UK.

Pragmatic and observational research·2026
Same journal

Relapse Predictors of Idiopathic Retroperitoneal Fibrosis: A Long-Term Cohort Study.

Pragmatic and observational research·2025
Same journal

INSIGHTS Asthma Pragmatic Registry - A Pragmatic Approach to High-Validity Real-World Evidence for Asthma.

Pragmatic and observational research·2025
See all related articles

Related Experiment Video

Updated: Jul 2, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K

Drug Repurposing in Crohn's Disease Using Danish Real-World Data.

Saeed Shakibfar1, Kristine H Allin2, Tine Jess2

  • 1Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.

Pragmatic and Observational Research
|February 26, 2024
PubMed
Summary
This summary is machine-generated.

This study identified 10 drugs that may reduce surgery risk for intestinal fibrosis in Crohn's disease (CD) patients. These findings support drug repurposing for treating this severe complication, addressing an unmet need.

Keywords:
Crohn’s diseasedrug repurposinginflammatory bowel diseaseintestinal fibrosismachine-learningreal-world data

More Related Videos

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.4K
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

10.0K

Related Experiment Videos

Last Updated: Jul 2, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K
Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.4K
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

10.0K

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Data Science

Background:

  • Intestinal fibrosis is a severe complication of Crohn's disease (CD) lacking effective pharmacological treatments.
  • Drug repurposing using electronic healthcare records (EHRs) offers a novel therapeutic avenue.
  • Identifying medications influencing fibrosis risk is crucial for patient management.

Purpose of the Study:

  • To identify existing medications associated with reduced or elevated risk of intestinal fibrosis in CD patients.
  • To leverage real-world data and artificial intelligence for drug repurposing strategies.
  • To address the unmet medical need for pharmacological interventions in CD-related intestinal fibrosis.

Main Methods:

  • Population-wide analysis of Danish EHRs (1996-2019) including patients aged 65+ with CD.
  • Utilized surgical procedures (proctocolectomy, ileocecal resection) as proxies for intestinal fibrosis.
  • Employed machine-learning driven survival analysis to identify drug-outcome associations.

Main Results:

  • Out of 9179 CD patients, 10.2% required surgery for intestinal fibrosis.
  • Ten drugs were linked to an increased risk of surgery.
  • Ten drugs were associated with a reduced risk of surgery.

Conclusions:

  • Drug repurposing holds promise for preventing surgery in CD patients with intestinal fibrosis.
  • The identified drugs warrant further investigation and clinical trials.
  • This study highlights the potential of real-world data and AI in discovering new therapeutic uses for existing medications.